Lupin receives approval for Dimethyl Fumarate Delayed-Release Capsules

Pharma major Lupin Limited (Lupin) announced that it has received approval for its Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Tecfidera® Delayed-Release Capsules, 120 mg and 240 mg, of Biogen, Inc. The product is expected to be launched shortly.

Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, are indicated for the treatment of patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Dimethyl Fumarate Delayed-Release Capsules (RLD: Tecfidera®) had an annual sales of approximately USD 3788 million in the U.S. (IQVIA MAT June 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.1038.75 as compared to the previous close of Rs. 1028.15. The total number of shares traded during the day was 98074 in over 4432 trades.

The stock hit an intraday high of Rs. 1047.85 and intraday low of 1012.95. The net turnover during the day was Rs. 101212058.

Source : Equity Bulls

Keywords